title: Rebuttal from Esler, Lambert, and Schlaich.
authors.affiliation: Baker IDI Heart and Diabetes Institute, Melbourne, Australia. murray.esler@bakeridi.edu.au
authors.forename: Murray
authors.initials: M
authors.lastname: Esler
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Lambert
authors.forename: Markus
authors.initials: M
authors.lastname: Schlaich
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D007668:Kidney / Q000294:innervation / Q000378:metabolism / Q000503:physiopathology; D012084:Renin-Angiotensin System; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents